FDA Warns Unilever Over Green Tea Health Claims

Law360, New York (September 8, 2010, 7:05 PM EDT) -- The U.S. Food and Drug Administration has warned Unilever PLC that certain health claims on the company’s Lipton Decaffeinated Green Tea would categorize the beverage as a new drug requiring agency approval.

The warning letter to the consumer products giant, dated Aug. 23, criticized passages on the Lipton website that claimed tea and “tea flavonoids” had been scientifically proven to reduce cholesterol in people with heart disease.

“The therapeutic claims on your website establish that the product is a drug because it is intended for use...
To view the full article, register now.